Human esophageal carcinomas frequently express the tumor‐rejection antigens of MAGE genes

Hiroshi Inoue, Masaki Mori, Jian Li, Koshi Mimori, Masayuki Honda, Hideaki Nakashima, Ken‐Ichi ‐I Mafune, Youichi Tanaka, Tsuyoshi Akiyoshi

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Thde human genes MAGE‐1 and ‐3 encode melanoma peptide antigens that are recognized bhd autologous cytotoxic T lymphocytes. Tumors expressing MAGE genes are potential targets for cancer immunotherapy, because MAGE genes are expressed only in tumor tissue and not in any normal tissue except testis and placenta. However, little is known about MAGE gene expression in human esophageal carcinoma. The purpose of this study was therefore to analyze MAGE gene status in human esophageal carcinoma. We studied the expression status of these genes in 42 surgical samples and in 12 cell lines of human esophageal carcinoma using the reverse transcription polymerase chain reaction (RT‐PCR). Various clinicopathological factors were also analyzed. No MAGE gene expression was seen in any of the 42 normal esophageal tissue specimens. In contrast, tumor tissue expressed MAGE‐1, ‐2, and ‐3 in 26, 18 and 24 specimens, respectively. Thirty‐three of 42 tumors expressed at least one MAGE gene. Significant clinicopathologic differences between the tumors were not observed, regardless of the presence or absence of MAGE gene expression. In cell lines, MAGE‐1, ‐2, and ‐3 gene expression was recognized in 5, 4 and 4 cell lines, respectively. This study demonstrates that MAGE genes are frequently expressed in clinical samples as well as in cell lines of esophageal carcinoma. The identification of MAGE genes, therefore, may open up a new modality of treatment, namely specific immunotherapy, for patients with esophageal carcinoma.

Original languageEnglish
Pages (from-to)523-526
Number of pages4
JournalInternational Journal of Cancer
Volume63
Issue number4
DOIs
Publication statusPublished - Jan 1 1995

Fingerprint

Carcinoma
Antigens
Gene Expression
Genes
Cell Line
Neoplasms
Immunotherapy
Melanoma-Specific Antigens
Cytotoxic T-Lymphocytes
Placenta
Reverse Transcription
Testis
Polymerase Chain Reaction
Peptides
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Human esophageal carcinomas frequently express the tumor‐rejection antigens of MAGE genes. / Inoue, Hiroshi; Mori, Masaki; Li, Jian; Mimori, Koshi; Honda, Masayuki; Nakashima, Hideaki; Mafune, Ken‐Ichi ‐I; Tanaka, Youichi; Akiyoshi, Tsuyoshi.

In: International Journal of Cancer, Vol. 63, No. 4, 01.01.1995, p. 523-526.

Research output: Contribution to journalArticle

Inoue, Hiroshi ; Mori, Masaki ; Li, Jian ; Mimori, Koshi ; Honda, Masayuki ; Nakashima, Hideaki ; Mafune, Ken‐Ichi ‐I ; Tanaka, Youichi ; Akiyoshi, Tsuyoshi. / Human esophageal carcinomas frequently express the tumor‐rejection antigens of MAGE genes. In: International Journal of Cancer. 1995 ; Vol. 63, No. 4. pp. 523-526.
@article{7d71d99083134340986325bd4ef34806,
title = "Human esophageal carcinomas frequently express the tumor‐rejection antigens of MAGE genes",
abstract = "Thde human genes MAGE‐1 and ‐3 encode melanoma peptide antigens that are recognized bhd autologous cytotoxic T lymphocytes. Tumors expressing MAGE genes are potential targets for cancer immunotherapy, because MAGE genes are expressed only in tumor tissue and not in any normal tissue except testis and placenta. However, little is known about MAGE gene expression in human esophageal carcinoma. The purpose of this study was therefore to analyze MAGE gene status in human esophageal carcinoma. We studied the expression status of these genes in 42 surgical samples and in 12 cell lines of human esophageal carcinoma using the reverse transcription polymerase chain reaction (RT‐PCR). Various clinicopathological factors were also analyzed. No MAGE gene expression was seen in any of the 42 normal esophageal tissue specimens. In contrast, tumor tissue expressed MAGE‐1, ‐2, and ‐3 in 26, 18 and 24 specimens, respectively. Thirty‐three of 42 tumors expressed at least one MAGE gene. Significant clinicopathologic differences between the tumors were not observed, regardless of the presence or absence of MAGE gene expression. In cell lines, MAGE‐1, ‐2, and ‐3 gene expression was recognized in 5, 4 and 4 cell lines, respectively. This study demonstrates that MAGE genes are frequently expressed in clinical samples as well as in cell lines of esophageal carcinoma. The identification of MAGE genes, therefore, may open up a new modality of treatment, namely specific immunotherapy, for patients with esophageal carcinoma.",
author = "Hiroshi Inoue and Masaki Mori and Jian Li and Koshi Mimori and Masayuki Honda and Hideaki Nakashima and Mafune, {Ken‐Ichi ‐I} and Youichi Tanaka and Tsuyoshi Akiyoshi",
year = "1995",
month = "1",
day = "1",
doi = "10.1002/ijc.2910630411",
language = "English",
volume = "63",
pages = "523--526",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Human esophageal carcinomas frequently express the tumor‐rejection antigens of MAGE genes

AU - Inoue, Hiroshi

AU - Mori, Masaki

AU - Li, Jian

AU - Mimori, Koshi

AU - Honda, Masayuki

AU - Nakashima, Hideaki

AU - Mafune, Ken‐Ichi ‐I

AU - Tanaka, Youichi

AU - Akiyoshi, Tsuyoshi

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Thde human genes MAGE‐1 and ‐3 encode melanoma peptide antigens that are recognized bhd autologous cytotoxic T lymphocytes. Tumors expressing MAGE genes are potential targets for cancer immunotherapy, because MAGE genes are expressed only in tumor tissue and not in any normal tissue except testis and placenta. However, little is known about MAGE gene expression in human esophageal carcinoma. The purpose of this study was therefore to analyze MAGE gene status in human esophageal carcinoma. We studied the expression status of these genes in 42 surgical samples and in 12 cell lines of human esophageal carcinoma using the reverse transcription polymerase chain reaction (RT‐PCR). Various clinicopathological factors were also analyzed. No MAGE gene expression was seen in any of the 42 normal esophageal tissue specimens. In contrast, tumor tissue expressed MAGE‐1, ‐2, and ‐3 in 26, 18 and 24 specimens, respectively. Thirty‐three of 42 tumors expressed at least one MAGE gene. Significant clinicopathologic differences between the tumors were not observed, regardless of the presence or absence of MAGE gene expression. In cell lines, MAGE‐1, ‐2, and ‐3 gene expression was recognized in 5, 4 and 4 cell lines, respectively. This study demonstrates that MAGE genes are frequently expressed in clinical samples as well as in cell lines of esophageal carcinoma. The identification of MAGE genes, therefore, may open up a new modality of treatment, namely specific immunotherapy, for patients with esophageal carcinoma.

AB - Thde human genes MAGE‐1 and ‐3 encode melanoma peptide antigens that are recognized bhd autologous cytotoxic T lymphocytes. Tumors expressing MAGE genes are potential targets for cancer immunotherapy, because MAGE genes are expressed only in tumor tissue and not in any normal tissue except testis and placenta. However, little is known about MAGE gene expression in human esophageal carcinoma. The purpose of this study was therefore to analyze MAGE gene status in human esophageal carcinoma. We studied the expression status of these genes in 42 surgical samples and in 12 cell lines of human esophageal carcinoma using the reverse transcription polymerase chain reaction (RT‐PCR). Various clinicopathological factors were also analyzed. No MAGE gene expression was seen in any of the 42 normal esophageal tissue specimens. In contrast, tumor tissue expressed MAGE‐1, ‐2, and ‐3 in 26, 18 and 24 specimens, respectively. Thirty‐three of 42 tumors expressed at least one MAGE gene. Significant clinicopathologic differences between the tumors were not observed, regardless of the presence or absence of MAGE gene expression. In cell lines, MAGE‐1, ‐2, and ‐3 gene expression was recognized in 5, 4 and 4 cell lines, respectively. This study demonstrates that MAGE genes are frequently expressed in clinical samples as well as in cell lines of esophageal carcinoma. The identification of MAGE genes, therefore, may open up a new modality of treatment, namely specific immunotherapy, for patients with esophageal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0028892953&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028892953&partnerID=8YFLogxK

U2 - 10.1002/ijc.2910630411

DO - 10.1002/ijc.2910630411

M3 - Article

C2 - 7591261

AN - SCOPUS:0028892953

VL - 63

SP - 523

EP - 526

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -